[go: up one dir, main page]

BR112021025516A2 - Processos para a fabricação de 4-(2-(pirrolidin-1-il)-4-(trifluorometil)benzil)piperazina-1-carboxilato de 1,1,1,3,3,3-hexafluoropropan-2-ila e da forma 2 do sal monocloridrato do mesmo - Google Patents

Processos para a fabricação de 4-(2-(pirrolidin-1-il)-4-(trifluorometil)benzil)piperazina-1-carboxilato de 1,1,1,3,3,3-hexafluoropropan-2-ila e da forma 2 do sal monocloridrato do mesmo

Info

Publication number
BR112021025516A2
BR112021025516A2 BR112021025516A BR112021025516A BR112021025516A2 BR 112021025516 A2 BR112021025516 A2 BR 112021025516A2 BR 112021025516 A BR112021025516 A BR 112021025516A BR 112021025516 A BR112021025516 A BR 112021025516A BR 112021025516 A2 BR112021025516 A2 BR 112021025516A2
Authority
BR
Brazil
Prior art keywords
hexafluoropropan
pyrrolidin
piperazine
carboxylate
trifluoromethyl
Prior art date
Application number
BR112021025516A
Other languages
English (en)
Inventor
A Grice Cheryl
G Grimm Kurt
K Jones Todd
Guercio Giuseppe
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of BR112021025516A2 publication Critical patent/BR112021025516A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/023—Preparation; Separation; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

PROCESSOS PARA A FABRICAÇÃO DE 4-(2-(PIRROLIDIN-1-IL)-4-(TRIFLUOROMETIL)BENZIL)PIPERAZINA-1-CARBOXILATO DE 1,1,1,3,3,3-HEXAFLUOROPROPAN-2-ILA E DA FORMA 2 DO SAL MONOCLORIDRATO DO MESMO. É aqui descrita a fabricação do inibidor da MAGL 4-(2-(pirrolidin-1-il)-4-(trifluorometil)benzil)piperazina-1-carboxilato de 1,1,1,3,3,3-hexafluoropropan-2-ila incluindo os seus sais.
BR112021025516A 2020-04-21 2021-04-19 Processos para a fabricação de 4-(2-(pirrolidin-1-il)-4-(trifluorometil)benzil)piperazina-1-carboxilato de 1,1,1,3,3,3-hexafluoropropan-2-ila e da forma 2 do sal monocloridrato do mesmo BR112021025516A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063013454P 2020-04-21 2020-04-21
PCT/IB2021/000277 WO2021214550A1 (en) 2020-04-21 2021-04-19 Synthesis of a monoacylglycerol lipase inhibitor

Publications (1)

Publication Number Publication Date
BR112021025516A2 true BR112021025516A2 (pt) 2022-11-01

Family

ID=76355536

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025516A BR112021025516A2 (pt) 2020-04-21 2021-04-19 Processos para a fabricação de 4-(2-(pirrolidin-1-il)-4-(trifluorometil)benzil)piperazina-1-carboxilato de 1,1,1,3,3,3-hexafluoropropan-2-ila e da forma 2 do sal monocloridrato do mesmo

Country Status (15)

Country Link
US (2) US11702393B2 (pt)
EP (1) EP4139288A1 (pt)
JP (1) JP2023523219A (pt)
KR (1) KR20230004622A (pt)
CN (1) CN115427403A (pt)
AR (1) AR121899A1 (pt)
AU (1) AU2021259496A1 (pt)
BR (1) BR112021025516A2 (pt)
CA (1) CA3175210A1 (pt)
CL (1) CL2022002895A1 (pt)
IL (1) IL297470A (pt)
MX (1) MX2022013224A (pt)
TW (1) TW202200564A (pt)
WO (1) WO2021214550A1 (pt)
ZA (1) ZA202211124B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508407A (ja) 2012-01-06 2015-03-19 アビデ セラピューティクス，インク． カルバメート化合物およびその製造および使用
BR112021025516A2 (pt) 2020-04-21 2022-11-01 H Lundbeck As Processos para a fabricação de 4-(2-(pirrolidin-1-il)-4-(trifluorometil)benzil)piperazina-1-carboxilato de 1,1,1,3,3,3-hexafluoropropan-2-ila e da forma 2 do sal monocloridrato do mesmo
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (pt) 1967-10-17 1970-06-01
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
WO1989011794A1 (fr) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Inhibiteur de la croissance de plantes
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
JP2527107B2 (ja) 1991-04-16 1996-08-21 日本新薬株式会社 固体分散体の製造方法
JPH07501073A (ja) 1991-11-22 1995-02-02 プロクター、エンド、ギャンブル、ファーマス−ティカルズ、インコーポレーテッド リゼドロネート遅延放出組成物
ATE138365T1 (de) 1991-11-27 1996-06-15 Du Pont Herbizide acylierte amino-(phenyl-oder-pyridinyl- oder thienyl-)phenyl derivate
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
ATE223704T1 (de) 1992-10-16 2002-09-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung von wachsmatrizes
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE69408873T2 (de) 1993-12-22 1998-07-09 Shell Int Research Verfahren zur herstellung von carbamaten
EP0827402A2 (en) 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine
JP2000500448A (ja) 1995-11-15 2000-01-18 ゼネカ リミテッド 除草性置換ピラゾール化合物
AU3440597A (en) 1996-07-02 1998-01-21 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1226115A4 (en) 1999-10-04 2006-03-15 Univ New Jersey Med CARBAMATE AND UREA
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
AU2003300702A1 (en) 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Process for preparing carbamates
CA2556268A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
EP1831218A2 (en) 2004-12-23 2007-09-12 F.Hoffmann-La Roche Ag Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
EA012589B1 (ru) 2004-12-30 2009-10-30 Янссен Фармацевтика Н.В. Производные фениламида 4-(бензил)пиперазин-1-карбоновой кислоты и родственные соединения в качестве модуляторов амида жирной кислоты гидролазы для лечения страхов, боли и других состояний
WO2007062266A2 (en) 2005-11-28 2007-05-31 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
EP1938804A1 (en) 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
MX2009006706A (es) 2006-12-22 2009-07-02 Astex Therapeutics Ltd Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
CN101711154A (zh) 2007-02-26 2010-05-19 科森生物科学公司 氨基甲酸酯化合物
FR2938341A1 (fr) 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
EP2328897A1 (en) 2008-07-16 2011-06-08 Schering Corporation Bicyclic heterocycle derivatives and their use as gpcr modulators
JP5576874B2 (ja) 2008-11-14 2014-08-20 ザ スクリプス リサーチ インスティテュート モノアシルグリセロールリパーゼの薬物標的化と関連する方法及び組成物
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
CN102548558B (zh) 2009-03-23 2014-04-30 Msdk.K.公司 具有Aurora A选择性抑制作用的氨基吡啶衍生物
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
RU2570662C9 (ru) 2009-11-03 2016-07-20 Байер Матириальсайенс Аг Фторуретаны в качестве добавки в фотополимерной композиции
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
JP2015508407A (ja) 2012-01-06 2015-03-19 アビデ セラピューティクス，インク． カルバメート化合物およびその製造および使用
EP3984997B1 (en) 2012-01-06 2025-07-30 Les Laboratoires Servier Therapeutically active compounds and their methods of use
EP2828253A1 (en) 2012-03-19 2015-01-28 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
EP2844247A4 (en) 2012-04-20 2015-11-25 Anderson Gaweco ROR MODULATORS AND ITS USES
SMT201800590T1 (it) 2012-11-02 2019-01-11 Vertex Pharma Composizioni farmaceutiche per il trattamento di malattie mediate da cftr
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
EP3016653A4 (en) 2013-07-03 2017-02-22 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
US10093630B2 (en) 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2016014975A2 (en) 2014-07-25 2016-01-28 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
CA2979537C (en) 2015-03-18 2023-08-29 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
CA2984480A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
US10899737B2 (en) * 2016-09-19 2021-01-26 Lundbeck La Jolla Research Center, Inc. Piperazine carbamates and methods of making and using same
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
PE20191239A1 (es) * 2016-11-16 2019-09-16 Abide Therapeutics Inc Formas cristalinas de un inhibidor de magl
MY199448A (en) * 2016-11-16 2023-10-29 H Lundbeck As Pharmaceutical formulations
JOP20200022A1 (ar) 2017-08-29 2020-02-02 Lundbeck La Jolla Research Center Inc مركبات حلقية لولبية وطرق تصنيعها واستخدامها
GEAP202215479A (en) 2018-05-15 2022-06-10 H Lundbeck As Magl inhibitors
BR112021025516A2 (pt) 2020-04-21 2022-11-01 H Lundbeck As Processos para a fabricação de 4-(2-(pirrolidin-1-il)-4-(trifluorometil)benzil)piperazina-1-carboxilato de 1,1,1,3,3,3-hexafluoropropan-2-ila e da forma 2 do sal monocloridrato do mesmo

Also Published As

Publication number Publication date
KR20230004622A (ko) 2023-01-06
AR121899A1 (es) 2022-07-20
US20240158360A1 (en) 2024-05-16
JP2023523219A (ja) 2023-06-02
TW202200564A (zh) 2022-01-01
AU2021259496A1 (en) 2022-11-10
IL297470A (en) 2022-12-01
CA3175210A1 (en) 2021-10-28
WO2021214550A1 (en) 2021-10-28
CL2022002895A1 (es) 2023-04-21
EP4139288A1 (en) 2023-03-01
MX2022013224A (es) 2022-11-14
US11702393B2 (en) 2023-07-18
US20210323938A1 (en) 2021-10-21
ZA202211124B (en) 2024-02-28
CN115427403A (zh) 2022-12-02

Similar Documents

Publication Publication Date Title
CY1124870T1 (el) Κρυσταλλικες μορφες ενος αναστολεα magl
BR112021025516A2 (pt) Processos para a fabricação de 4-(2-(pirrolidin-1-il)-4-(trifluorometil)benzil)piperazina-1-carboxilato de 1,1,1,3,3,3-hexafluoropropan-2-ila e da forma 2 do sal monocloridrato do mesmo
MX2023000085A (es) Compuestos antiproliferativos y metodos para utilizarlos.
CO4940418A1 (es) Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
MX2022010495A (es) Forma cristalina de 6-(ciclopropanocarboxamido)-4-((2-metoxi-3- (1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3) piridazin-3-carboxamida.
EP3948463A4 (en) TELEOPERATION FOR EXCEPTION HANDLING
EA202191051A1 (ru) Ингибитор аврора-киназы a для применения для лечения нейробластомы
MX2021000107A (es) Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidro piridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-tria zin-6-carbonitrilo.
IL278854B2 (en) Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile
BR0116063A (pt) Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos
MX390378B (es) Compuesto del inhibidor fgfr4 cristalino y usos del mismo.
BR112015012512A2 (pt) trans-4-{2-[4-(2,3-diclorofenil)-piperazina-1-il]-etil}-n,n-dimetilcarbamoil-ciclo-hexilamina para o tratamento de sintomas negativos da esquizofrenia
MX2019001007A (es) Uso novedoso de nectinib y una sal farmaceuticamente aceptable del mismo en el tratamiento contra enfermedades.
MX2024012883A (es) Compuestos de liberacion de gamma-hidroxibutirato y procesos para fabricar y usar los mismos
AR127545A1 (es) Formas cristalinas de un inhibidor de la monoacilglicerol lipasa
AR120462A1 (es) Formas cristalinas de un inhibidor de magl
ATE439133T1 (de) Verwendung von tyrosin-kinase-hemmern zur behandlung von diabetes
PE20051138A1 (es) BLOQUEADORES DE Kv1.5 REFERIDOS AL AUMENTO SELECTIVO DE LA CONTRACTILIDAD
MX2024011731A (es) Composicion para el tratamiento de heridas
PL407396A1 (pl) 1,1-ditlenek 3-benzoilo-4-hydroksy-2-{2-[4-(2-metoksyfenylo)piperazyn-1-ylo]2-oksoetylo}-2H-1,2-benzotiazyny o aktywności przeciwzapalnej i przeciwbólowej oraz sposób jego wytwarzania
GEAP202516658A (en) Ripk1 inhibitors and methods of use
ATE326970T1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
HK40051930A (en) Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile
PL407397A1 (pl) 1,1-ditlenek 3-(4-bromobenzoilo)-4-hydroksy-2-{2-[4-(2-pirymidylo)piperazyn-1-ylo]-2-oksoetylo}-2H-1,2-benzotiazyny o aktywności przeciwzapalnej i przeciwbólowej oraz sposób jego wytwarzania
ES51625A1 (es) Una disposición para sacrificar y preparar por pares reses vacunas ligeras y ganado menor pesado.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]